Is Genotype 3 of the Hepatitis C Virus the New Villain?

被引：113

作者：

Goossens, Nicolas ^{[1
]}

Negro, Francesco ^{[1
,2
]}

机构：

[1] Univ Hosp Geneva, Div Gastroenterol & Hepatol, CH-1211 Geneva 4, Switzerland

[2] Univ Hosp Geneva, Div Clin Pathol, CH-1211 Geneva 4, Switzerland

来源：

HEPATOLOGY | 2014年 / 59卷 / 06期

基金：

瑞士国家科学基金会;

关键词：

SUSTAINED VIROLOGICAL RESPONSE; TRIGLYCERIDE TRANSFER PROTEIN; ACTIVATED-RECEPTOR-ALPHA; TREATMENT-NAIVE PATIENTS; HEPATOCELLULAR-CARCINOMA; PLUS RIBAVIRIN; HCV GENOTYPE; PEGINTERFERON ALPHA-2B; RISK-FACTOR; CHOLESTEROL-METABOLISM;

D O I：

10.1002/hep.26905

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Genotype 3 of the hepatitis C virus (HCV) has been long considered an easy-to-treat infection, with higher cure rates (similar to 70%) than other viral genotypes with the standard combination of pegylated interferon-alpha and ribavirin. However, the relative insensitivity of this genotype to most protease inhibitors and the recent unexpected data on decreased effectiveness of sofosbuvir have raised questions on how to achieve universal cure, a goal that seems reasonable for other genotypes. In addition, increasing clinical and experimental data show that HCV genotype 3 may be associated not only with severe steatosis, but also with accelerated fibrosis progression rate and increased oncogenesis. Conclusion: Currently available data suggest that we should increase our efforts to understand the virology and pathogenesis of HCV genotype 3, aiming at better and more potent, genotype-targeted treatments.

引用

页码：2403 / 2412

页数：10

共 74 条

[21] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[22] Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses [J].

Gottwein, Judith M. ;

Scheel, Troels K. H. ;

Jensen, Tanja B. ;

Ghanem, Lubna ;

Bukh, Jens .

GASTROENTEROLOGY, 2011, 141 (03) :1067-1079

[23] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

[24] Hepatitis C Virus Core Protein Decreases Lipid Droplet Turnover A MECHANISM FOR CORE-INDUCED STEATOSIS [J].

Harris, Charles ;

Herker, Eva ;

Farese, Robert V., Jr. ;

Ott, Melanie .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (49) :42615-42625

[25] Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C [J].

Hézode, C ;

Roudot-Thoraval, F ;

Nguyen, S ;

Grenard, P ;

Julien, B ;

Zafrani, ES ;

Pawlostky, JM ;

Dhumeaux, D ;

Lotersztajn, S ;

Mallat, A .

HEPATOLOGY, 2005, 42 (01) :63-71

[26] Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections [J].

Hézode, C ;

Roudot-Thoraval, F ;

Zafrani, ES ;

Dhumeaux, D ;

Pawlotsky, JM .

JOURNAL OF VIRAL HEPATITIS, 2004, 11 (05) :455-458

[27]

Hofer H, 2002, AM J GASTROENTEROL, V97, P2880, DOI 10.1111/j.1572-0241.2002.07056.x

[28] Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis [J].

Hourigan, LF ;

Macdonald, GA ;

Purdie, D ;

Whitehall, VLJ ;

Shorthouse, C ;

Clouston, A ;

Powell, EE .

HEPATOLOGY, 1999, 29 (04) :1215-1219

[29] Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial [J].

Jacobson, Ira M. ;

Brown, Robert S., Jr. ;

Freilich, Bradley ;

Afdhal, Nezam ;

Kwo, Paul Y. ;

Santoro, John ;

Becker, Scott ;

Wakil, Adil E. ;

Pound, David ;

Godofsky, Eliot ;

Strauss, Robert ;

Bernstein, David ;

Flamm, Steven ;

Pauly, Mary Pat ;

Mukhopadhyay, Pabak ;

Griffel, Louis H. ;

Brass, Clifford A. .

HEPATOLOGY, 2007, 46 (04) :971-981

[30] Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options [J].

Jacobson, Ira M. ;

Gordon, Stuart C. ;

Kowdley, Kris V. ;

Yoshida, Eric M. ;

Rodriguez-Torres, Maribel ;

Sulkowski, Mark S. ;

Shiffman, Mitchell L. ;

Lawitz, Eric ;

Everson, Gregory ;

Bennett, Michael ;

Schiff, Eugene ;

Al-Assi, M. Tarek ;

Subramanian, G. Mani ;

An, Di ;

Lin, Ming ;

McNally, John ;

Brainard, Diana ;

Symonds, William T. ;

McHutchison, John G. ;

Patel, Keyur ;

Feld, Jordan ;

Pianko, Stephen ;

Nelson, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1867-1877

← 1 2 3 4 5 6 7 8 →